ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 57.86 USD -1.33%
Market Cap: 1.2B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

ANI Pharmaceuticals Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ANI Pharmaceuticals Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Total Receivables
$202.5m
CAGR 3-Years
23%
CAGR 5-Years
23%
CAGR 10-Years
30%
Johnson & Johnson
NYSE:JNJ
Total Receivables
$16.2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Total Receivables
$14.9B
CAGR 3-Years
8%
CAGR 5-Years
23%
CAGR 10-Years
17%
Pfizer Inc
NYSE:PFE
Total Receivables
$15.1B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
4%
Merck & Co Inc
NYSE:MRK
Total Receivables
$12.2B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Total Receivables
$12.1B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
13%
No Stocks Found

ANI Pharmaceuticals Inc
Glance View

Market Cap
1.2B USD
Industry
Pharmaceuticals

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

ANIP Intrinsic Value
96.33 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is ANI Pharmaceuticals Inc's Total Receivables?
Total Receivables
202.5m USD

Based on the financial report for Sep 30, 2024, ANI Pharmaceuticals Inc's Total Receivables amounts to 202.5m USD.

What is ANI Pharmaceuticals Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
30%

Over the last year, the Total Receivables growth was 13%. The average annual Total Receivables growth rates for ANI Pharmaceuticals Inc have been 23% over the past three years , 23% over the past five years , and 30% over the past ten years .

Back to Top